News in Brief
Health - 08:01
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Pharmacology - Sep 19
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar and Mekinist in advanced melanoma
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar and Mekinist in advanced melanoma
wire - news in brief
Category
Results 51 - 100 of 458.
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.
Molecular glue degraders are a new class of drugs that work by facilitating an interaction between a disease-causing target protein and a ubiquitin ligase complex, tagging the target protein for degradation.
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
Two talented young researchers at Empa will be given the opportunity to develop their own research area over a five-year period with the help of an ERC Starting Grant from the European Research Counc
ETH has once again been highly successful in the awarding of this year's ERC Starting Grants for young researchers, with the European Research Council (ERC) approving a total of CHF 21.4 million in funding for 12 ETH project submissions.
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
How the Swiss fared under partial lockdown
A joint study by EPFL, the Idiap Research Institute and the University of Lausanne's Institute of Psychology has provided us with a unique snapshot of how Swiss residents experienced the partial lockdown measures resulting from the coronavirus pandemic. The findings include gender disparities, doubts about the future and hopes for change.
A joint study by EPFL, the Idiap Research Institute and the University of Lausanne's Institute of Psychology has provided us with a unique snapshot of how Swiss residents experienced the partial lockdown measures resulting from the coronavirus pandemic. The findings include gender disparities, doubts about the future and hopes for change.
Organoid? was launched today. It aims at validating organoids as faithful models of human biology, combining single-cell profiling and organoid technology.
As impressive as they may be, the latest AI systems are still no match for humans. Benjamin Grewe pushes for tomorrow's intelligent machines to learn the way young children do.
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
The fact that there are many different types of infinities is one of the big puzzles in mathematics.
The review paper "Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic" was co-authored by 34 contributors from around the world. What was Eawag's contribution? Eberhard Morgenroth: For May 2020 I had been invited to participate in the "International Water Summit" at the Ben-Gurion University in Israel.
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.
In the body, so-called programmed cell death prevents cells with irreparable damage from surviving and turning into cancer cells. In the "EMBO Journal", researchers at the University of Basel's Biozentrum, report how a certain protein variant thwarts the self-destruction and thus promotes the growth of breast cancer cells.
The pornographic sequences broadcast live on the web feature between 300,000 and 500,000 people - the vast majority of them women - for a largely male clientele of at least 500 million followers.
Thanks to technology from ETH spin-off Neustark, concrete recycling plants can store carbon dioxide over the long term.
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros
An interactive video game created by researchers and students in the College of Humanities (CDH) and UNIL Gamelab, in collaboration with the Initiative for Media Innovation (IMI) and Le Temps, allows
Two EPFL students have compared the ability of a forest in Vaud Canton to protect against avalanches before and after it was ravaged by fire in 2018.
UZH Introduces Five New University Research Priority Programs
The University of Zurich is introducing five new University Research Priority Programs focusing on equal opportunities, human reproduction, rare diseases, digital religions and basic principles of learning.
The University of Zurich is introducing five new University Research Priority Programs focusing on equal opportunities, human reproduction, rare diseases, digital religions and basic principles of learning.
Summer series: science as a vocation. Kumar Varoon Agrawal, a tenure-track assistant professor who holds the Gaznat Chair for Advanced Separations at EPFL Valais-Wallis, is developing advanced membranes for the molecular separation of industrial product streams, mainly for CO2 capture.
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
Summer series: Careers in research. Florian Breider, who heads EPFL's Central Environmental Laboratory (CEL), knew from a young age that he wanted to become a scientist.
The software platform, NeuroKey, interfaces with multiple brain signal acquisition sources and devices, extending the reach of brain-computer interface applications GENEVA, SWITZERLAND & SALT LAKE CITY, UTAH, USA - The Wyss Center for Bio and Neuroengineering has granted a worldwide license to Blackrock Microsystems to commercialize its neural signal processing and decoding software platform for research and clinical applications.
Pushing the boundaries of implantable neuro-device development Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont,
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
News in Brief
Health - 08:01
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Pharmacology - Sep 19
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar and Mekinist in advanced melanoma
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar and Mekinist in advanced melanoma